INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37001, 23412, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37002, 23413, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37003, 23986, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37004, 23988, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37005, 23989, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37006, 25640, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37007, 25641, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37008, 25642, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37009, 25643, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37010, 26235, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37011, 26236, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37012, 28462, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37013, 28463, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37014, 28470, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37015, 28471, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37016, 28562, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37017, 28563, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37018, 28564, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37019, 28565, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37020, 28566, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37021, 29602, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37022, 29603, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37023, 29683, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37024, 29771, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37025, 29772, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37026, 29773, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37027, 29774, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37028, 30038, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37029, 30039, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37030, 30040, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37031, 30293, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37032, 31806, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37033, 32614, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37034, 32615, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37035, 32616, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37036, 32617, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37037, 32618, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37038, 32619, 'Ceftriaxone', 'Hyperbilirubinemia', 'Hyperbilirubinemic neonates, especially premature, should not be treated with ceftriaxone for injection.  Studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to possible risk of bilirubin encephalopathy in these patients.', '3', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37039, 51, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37040, 1860, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37041, 2216, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37042, 2217, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37043, 2218, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37044, 2220, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37045, 2268, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37046, 2286, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37047, 2287, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37048, 2289, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37049, 2291, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37050, 4230, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37051, 4231, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37052, 6830, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37053, 7503, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37054, 8047, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37055, 9177, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37056, 9939, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37057, 9940, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37058, 11643, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37059, 12639, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37060, 12640, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37061, 12641, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37062, 12709, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37063, 12941, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37064, 15995, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37065, 15996, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37066, 15998, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37067, 16047, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37068, 16048, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37069, 16049, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37070, 16064, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37071, 16065, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37072, 16067, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37073, 16068, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37074, 17727, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37075, 18326, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37076, 18327, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37077, 18328, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37078, 18369, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37079, 18370, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37080, 18371, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37081, 18372, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37082, 18373, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37083, 18495, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37084, 18751, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37085, 21055, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37086, 21338, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37087, 22008, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37088, 22615, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37089, 22616, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37090, 23412, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37091, 23413, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37092, 23986, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37093, 23988, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37094, 23989, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37095, 25640, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37096, 25641, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37097, 25642, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37098, 25643, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37099, 26235, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37100, 26236, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37101, 28462, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37102, 28463, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37103, 28470, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37104, 28471, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37105, 28562, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37106, 28563, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37107, 28564, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37108, 28565, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37109, 28566, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37110, 29602, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37111, 29603, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37112, 29683, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37113, 29771, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37114, 29772, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37115, 29773, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37116, 29774, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37117, 30038, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37118, 30039, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37119, 30040, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37120, 30293, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37121, 31806, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37122, 32614, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37123, 32615, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37124, 32616, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37125, 32617, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37126, 32618, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37127, 32619, 'Ceftriaxone', 'Gallbladder Diseases', 'Ceftriaxone can precipitate in the gallbladder.  Sonographic abnormalities and symptoms of gallbladder disease have been reported.  Therapy with ceftriaxone should be administered cautiously in patients with preexisting disease of the gallbladder, biliary tract, or liver.  Serial abdominal ultrasonography may be appropriate during therapy.  The drug should be discontinued in patients who develop signs and symptoms suggestive of gallbladder disease while being treated with ceftriaxone.', '2', 'Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988):  858|Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989):  165|Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991):  1251-4|Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992):  329-30|Lopez AJ, O''Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991):  712-4|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998):  662-3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37128, 51, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37129, 1860, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37130, 2216, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37131, 2217, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37132, 2218, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37133, 2220, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37134, 2268, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37135, 2286, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37136, 2287, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37137, 2289, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37138, 2291, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37139, 4230, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37140, 4231, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37141, 6830, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37142, 7503, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37143, 8047, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37144, 9177, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37145, 9939, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37146, 9940, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37147, 11643, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37148, 12639, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37149, 12640, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37150, 12641, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37151, 12709, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37152, 12941, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37153, 15995, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37154, 15996, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37155, 15998, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37156, 16047, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37157, 16048, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37158, 16049, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37159, 16064, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37160, 16065, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37161, 16067, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37162, 16068, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37163, 17727, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37164, 18326, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37165, 18327, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37166, 18328, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37167, 18369, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37168, 18370, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37169, 18371, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37170, 18372, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37171, 18373, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37172, 18495, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37173, 18751, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37174, 21055, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37175, 21338, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37176, 22008, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37177, 22615, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37178, 22616, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37179, 23412, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37180, 23413, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37181, 23986, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37182, 23988, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37183, 23989, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37184, 25640, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37185, 25641, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37186, 25642, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37187, 25643, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37188, 26235, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37189, 26236, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37190, 28462, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37191, 28463, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37192, 28470, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37193, 28471, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37194, 28562, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37195, 28563, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37196, 28564, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37197, 28565, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37198, 28566, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37199, 29602, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37200, 29603, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37201, 29683, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37202, 29771, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37203, 29772, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37204, 29773, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37205, 29774, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37206, 30038, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37207, 30039, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37208, 30040, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37209, 30293, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37210, 31806, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37211, 32614, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37212, 32615, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37213, 32616, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37214, 32617, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37215, 32618, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37216, 32619, 'Ceftriaxone', 'Pancreatitis', 'Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone.  Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition).  A cofactor role of ceftriaxone-related biliary precipitation cannot be ruled out.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37217, 51, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37218, 1860, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37219, 2216, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37220, 2217, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37221, 2218, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37222, 2220, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37223, 2268, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37224, 2286, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37225, 2287, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37226, 2289, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37227, 2291, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37228, 4230, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37229, 4231, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37230, 6830, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37231, 7503, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37232, 8047, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37233, 9177, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37234, 9939, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37235, 9940, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37236, 11643, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37237, 12639, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37238, 12640, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37239, 12641, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37240, 12709, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37241, 12941, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37242, 15995, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37243, 15996, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37244, 15998, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37245, 16047, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37246, 16048, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37247, 16049, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37248, 16064, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37249, 16065, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37250, 16067, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37251, 16068, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37252, 17727, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37253, 18326, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37254, 18327, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37255, 18328, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37256, 18369, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37257, 18370, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37258, 18371, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37259, 18372, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37260, 18373, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37261, 18495, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37262, 18751, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37263, 21055, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37264, 21338, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37265, 22008, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37266, 22615, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37267, 22616, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37268, 23412, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37269, 23413, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37270, 23986, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37271, 23988, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37272, 23989, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37273, 25640, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37274, 25641, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37275, 25642, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37276, 25643, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37277, 26235, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37278, 26236, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37279, 28462, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37280, 28463, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37281, 28470, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37282, 28471, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37283, 28562, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37284, 28563, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37285, 28564, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37286, 28565, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37287, 28566, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37288, 29602, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37289, 29603, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37290, 29683, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37291, 29771, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37292, 29772, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37293, 29773, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37294, 29774, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37295, 30038, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37296, 30039, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37297, 30040, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37298, 30293, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37299, 31806, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37300, 32614, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37301, 32615, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37302, 32616, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37303, 32617, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37304, 32618, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37305, 32619, 'Ceftriaxone', 'Vitamin K Deficiency', 'Alterations in prothrombin times have rarely occurred in patients treated with ceftriaxone.  Patients with impaired vitamin K synthesis or low vitamin K stores, such a patients with chronic hepatic disease and malnutrition, require monitoring of prothrombin time during treatment.  Vitamin K administration (10 mg per week) might be needed if prothrombin time is prolonged before or during therapy.', '2', '"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37306, 51, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37307, 1860, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37308, 2216, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37309, 2217, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37310, 2218, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37311, 2220, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37312, 2268, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37313, 2286, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37314, 2287, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37315, 2289, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37316, 2291, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37317, 4230, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37318, 4231, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37319, 6830, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37320, 7503, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37321, 8047, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37322, 9177, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37323, 9939, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37324, 9940, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37325, 11643, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37326, 12639, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37327, 12640, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37328, 12641, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37329, 12709, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37330, 12941, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37331, 15995, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37332, 15996, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37333, 15998, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37334, 16047, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37335, 16048, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37336, 16049, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37337, 16064, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37338, 16065, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37339, 16067, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37340, 16068, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37341, 17727, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37342, 18326, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37343, 18327, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37344, 18328, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37345, 18369, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37346, 18370, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37347, 18371, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37348, 18372, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37349, 18373, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37350, 18495, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37351, 18751, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37352, 21055, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37353, 21338, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37354, 22008, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37355, 22615, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37356, 22616, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37357, 23412, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37358, 23413, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37359, 23986, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37360, 23988, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37361, 23989, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37362, 25640, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37363, 25641, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37364, 25642, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37365, 25643, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37366, 26235, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37367, 26236, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37368, 28462, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37369, 28463, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37370, 28470, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37371, 28471, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37372, 28562, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37373, 28563, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37374, 28564, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37375, 28565, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37376, 28566, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37377, 29602, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37378, 29603, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37379, 29683, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37380, 29771, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37381, 29772, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37382, 29773, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37383, 29774, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37384, 30038, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37385, 30039, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37386, 30040, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37387, 30293, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37388, 31806, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37389, 32614, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37390, 32615, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37391, 32616, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37392, 32617, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37393, 32618, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37394, 32619, 'Ceftriaxone', 'Liver Diseases', 'Ceftriaxone is eliminated by both renal and hepatobiliary excretion.  At usual dosages (i.e. 1 to 2 g/day), adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored periodically, and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, ceftriaxone dosage should not exceed 2 grams per day without close monitoring of serum concentrations.', '2', 'Stoeckel K, Koup JR "Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model." Am J Med 77 (1984):  26-32|Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ "Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults." Antimicrob Agents Chemother 22 (1982):  816-23|McNamara PJ, Stoeckel K, Ziegler WH "Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose." Eur J Clin Pharmacol 22 (1982):  71-5|Wise R, Wright N "The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction." Infection 13 (1985):  s145-50|Fraschini F, Braga PC, Scarpazza G, et al. "Human pharmacokinetics and distribution in various tissues of ceftriaxone." Chemotherapy 32 (1986):  192-9|Holazo, AA, Patel IH, Weinfeld RE, Konikoff JJ, Parsonnet M "Ceftriaxone pharmacokinetics following multiple intramuscular dosing." Eur J Clin Pharmacol 30 (1986):  109-12|Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988):  261-6|Hary L, Andrejak M, Leleu S, et al. "The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites." Eur J Clin Pharmacol 36 (1989):  613-6|Patel IH, Chen S, Parsonnet M, et al. "Pharmacokinetics of ceftriaxone in humans." Antimicrob Agents Chemother 20 (1981):  634-41|Stoeckel K, Tuerk H, Trueb V, McNamara PJ "Single-dose ceftriaxone kinetics in liver insufficiency." Clin Pharmacol Ther 36 (1984):  500-9|Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E "Single-dose ceftriaxone kinetics in functionally anephric patients." Clin Pharmacol Ther 33 (1983):  633-41|Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984):  83-7|Kowalsky SF, Echols RM, Parker MA "Pharmacokinetics of ceftriaxone in subjects with renal insufficiency." Clin Pharm 4 (1985):  177-81|Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983):  529-32|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37395, 51, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37396, 1860, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37397, 2216, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37398, 2217, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37399, 2218, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37400, 2220, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37401, 2268, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37402, 2286, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37403, 2287, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37404, 2289, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37405, 2291, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37406, 4230, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37407, 4231, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37408, 6830, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37409, 7503, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37410, 8047, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37411, 9177, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37412, 9939, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37413, 9940, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37414, 11643, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37415, 12639, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37416, 12640, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37417, 12641, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37418, 12709, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37419, 12941, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37420, 15995, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37421, 15996, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37422, 15998, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37423, 16047, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37424, 16048, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37425, 16049, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37426, 16064, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37427, 16065, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37428, 16067, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37429, 16068, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37430, 17727, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37431, 18326, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37432, 18327, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37433, 18328, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37434, 18369, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37435, 18370, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37436, 18371, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37437, 18372, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37438, 18373, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37439, 18495, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37440, 18751, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37441, 21055, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37442, 21338, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37443, 22008, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37444, 22615, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37445, 22616, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37446, 23412, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37447, 23413, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37448, 23986, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37449, 23988, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37450, 23989, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37451, 25640, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37452, 25641, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37453, 25642, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37454, 25643, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37455, 26235, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37456, 26236, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37457, 28462, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37458, 28463, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37459, 28470, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37460, 28471, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37461, 28562, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37462, 28563, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37463, 28564, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37464, 28565, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37465, 28566, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37466, 29602, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37467, 29603, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37468, 29683, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37469, 29771, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37470, 29772, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37471, 29773, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37472, 29774, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37473, 30038, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37474, 30039, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37475, 30040, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37476, 30293, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37477, 31806, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37478, 32614, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37479, 32615, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37480, 32616, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37481, 32617, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37482, 32618, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37483, 32619, 'Ceftriaxone', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37484, 5758, 'Cefoxitin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37485, 24249, 'Cefoxitin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37486, 25014, 'Cefoxitin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37487, 25015, 'Cefoxitin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37488, 25237, 'Cefoxitin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37489, 5758, 'Cefoxitin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37490, 24249, 'Cefoxitin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37491, 25014, 'Cefoxitin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37492, 25015, 'Cefoxitin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37493, 25237, 'Cefoxitin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37494, 5758, 'Cefoxitin', 'Heart Failure', 'Parenteral cefoxitin sodium contains approximately 53 mg (2.3 mEq) of sodium per each gram of cefoxitin activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37495, 24249, 'Cefoxitin', 'Heart Failure', 'Parenteral cefoxitin sodium contains approximately 53 mg (2.3 mEq) of sodium per each gram of cefoxitin activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37496, 25014, 'Cefoxitin', 'Heart Failure', 'Parenteral cefoxitin sodium contains approximately 53 mg (2.3 mEq) of sodium per each gram of cefoxitin activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37497, 25015, 'Cefoxitin', 'Heart Failure', 'Parenteral cefoxitin sodium contains approximately 53 mg (2.3 mEq) of sodium per each gram of cefoxitin activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37498, 25237, 'Cefoxitin', 'Heart Failure', 'Parenteral cefoxitin sodium contains approximately 53 mg (2.3 mEq) of sodium per each gram of cefoxitin activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37499, 5758, 'Cefoxitin', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (37500, 24249, 'Cefoxitin', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
